Penicillin G Sodium

Gas Gangrene, Botulism, Anthrax + 20 more

Treatment

20 Active Studies for Penicillin G Sodium

Treatment for

Gas Gangrene

What is Penicillin G Sodium

Benzylpenicillin

The Generic name of this drug

Treatment Summary

Penicillin G (Benzylpenicillin) is a type of antibiotic used to treat bacterial infections. It is usually given intravenously or intramuscularly as it is not easily absorbed orally. Penicillin G is typically used to treat infections caused by certain gram-positive bacteria, such as Streptococcus pneumoniae, Streptococcus agalactiae and Staphylococcus. It can also be used in some cases against gram-negative bacteria such as Neisseria meningitidis and Pasteurella. Penicillin G is not usually used to treat anaerobic infections.

Bicillin L-A

is the brand name

Penicillin G Sodium Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Bicillin L-A

Benzylpenicillin

1952

Effectiveness

How Penicillin G Sodium Affects Patients

Penicillin G is an antibiotic used to treat bacterial infections caused by certain types of bacteria. It works by preventing the bacteria from forming their cell walls, which kills them. Penicillin G is effective against both gram-positive and gram-negative bacteria, and is resistant to many types of beta-lactamases that can break down other antibiotics.

How Penicillin G Sodium works in the body

Penicillin G works by blocking specific proteins inside the bacterial cell wall. This stops the cell from being able to build its wall, causing it to break apart and die. Penicillin G is also believed to interfere with molecules that stop autolysis, which helps the cell wall break down even further.

When to interrupt dosage

The prescribed dose of Penicillin G Sodium is contingent upon the recognized ailment, which includes rat bite fever, Haverhill fever and Actinomycosis. The amount of dosage fluctuates as per the technique of delivery (e.g. Intramuscular; Intravenous or Injection, suspension) featured in the table beneath.

Condition

Dosage

Administration

Anthrax

, 5000000.0 [iU], 20000000.0 [iU], 5000000.0 [USP'U], 1200000.0 [iU]/mL, 5000000.0 units, 1000000.0 units, 10000000.0 units, 500000.0 units, 600000.0 [iU]/mL, 2400000.0 [iU]/mL, 100000.0 [iU]/mL, 200000.0 [iU]/mL, 300000.0 [iU]/mL, 1000000.0 [iU], 900000.0 [iU]/mL, 500000.0 units/mL, 1200000.0 units/mL, 250000.0 units/mL, 900000.0 units/mL, 300000.0 units/mL

Injection, powder, for solution - Intramuscular; Intravenous, , Intramuscular; Intravenous, Injection, powder, for solution, Intramuscular, Injection, suspension, Injection, suspension - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular; Intrapleural; Intrathecal; Intravenous, Intravenous, Powder, for solution - Intravenous, Intramuscular; Intrapleural; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intravenous, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Topical, Powder, for solution - Intramuscular; Intravenous; Topical, Suspension, Powder, for solution - Intramuscular, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution - Intravenous, Suspension - Intramuscular, Suspension - Oral

Rat-Bite Fever

Bacterial Meningitis

Empyema

Pericarditis

Gonorrhea

Actinomycosis

Communicable Diseases

Rat-Bite Fever

Listeriosis

Meningitis, Meningococcal

Rheumatic Fever

Lockjaw

Endocarditis

Botulism

Diphtheria

Syphilis

Fusospirochetosis

Sepsis

Gas Gangrene

Warnings

Penicillin G Sodium has one contraindication and should not be administered together with any of the conditions listed in the below table.

Penicillin G Sodium Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Benzylpenicillin may interact with Pulse Frequency

There are 20 known major drug interactions with Penicillin G Sodium.

Common Penicillin G Sodium Drug Interactions

Drug Name

Risk Level

Description

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Benzylpenicillin.

Adefovir dipivoxil

Minor

The excretion of Adefovir dipivoxil can be decreased when combined with Benzylpenicillin.

Chlormadinone

Minor

The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Benzylpenicillin.

Cidofovir

Minor

The excretion of Cidofovir can be decreased when combined with Benzylpenicillin.

Cloprostenol

Minor

The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Benzylpenicillin.

Penicillin G Sodium Toxicity & Overdose Risk

The toxic dose of cephalosporin in rats is 8900 mg/kg. Taking too much can lead to seizures, a decrease in white blood cells, and other neurological reactions. If cephalosporin is taken for more than two weeks at high doses, it can also cause a drop in the number of neutrophils in the blood.

Penicillin G Sodium Novel Uses: Which Conditions Have a Clinical Trial Featuring Penicillin G Sodium?

85 active clinical trials are assessing the potential of Penicillin G Sodium in treating Pneumonia, Acute Rheumatic Fever and Gram-Negative Bacterial Infections.

Condition

Clinical Trials

Trial Phases

Pneumonia

17 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4

Lockjaw

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Rheumatic Fever

0 Actively Recruiting

Botulism

0 Actively Recruiting

Bacterial Meningitis

0 Actively Recruiting

Fusospirochetosis

0 Actively Recruiting

Meningitis, Meningococcal

0 Actively Recruiting

Anthrax

1 Actively Recruiting

Phase 2

Gram-Negative Bacterial Infections

0 Actively Recruiting

Gas Gangrene

0 Actively Recruiting

Empyema

1 Actively Recruiting

Phase 4

Listeriosis

0 Actively Recruiting

Actinomycosis

0 Actively Recruiting

Diphtheria

0 Actively Recruiting

Rat-Bite Fever

0 Actively Recruiting

Endocarditis

0 Actively Recruiting

Pericarditis

2 Actively Recruiting

Phase 2, Phase 3

Endocarditis

0 Actively Recruiting

Sepsis

0 Actively Recruiting

Penicillin G Sodium Reviews: What are patients saying about Penicillin G Sodium?

Patient Review

6/12/2009

Penicillin G Sodium for Bacterial Pneumonia caused by Streptococcus

The needle is quite long, but it does the job. I was a bit sore afterward, but nothing too bad.

Patient Review

10/2/2013

Penicillin G Sodium for Pus in Lungs caused by Bacteria Clostridium Perfringens

This caused me to stop breathing and cough while I was in the hospital.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about penicillin g sodium

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is penicillin G sodium used for?

"Penicillin G sodium is an antibiotic used to treat severe infections, such as strep throat, meningitis, anthrax, pneumonia, gonorrhea, and syphilis."

Answered by AI

What does penicillin G contain?

"Penicillin G potassium is a natural penicillin. Its chemical designation is 4-Thia-1- azabicyclo[3.2. 0]heptane-2-carboxylic acid,3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-, monopotassium salt, [2S-(2α, 5α, 6β)]. It is crystalline."

Answered by AI

What is penicillin G sodium salt?

"Penicillin G Sodium is the sodium salt form of benzylpenicillin, a broad-spectrum penicillin antibiotic with bactericidal activity. Benzylpenicillin sodium binds to and inactivates penicillin-binding proteins located on the bacterial cell wall."

Answered by AI

What is the difference between penicillin G potassium and penicillin G sodium?

"Penicillin G Sodium is usually given to patients who can't take Penicillin G Potassium (for example, patients with kidney problems). Most patients who need penicillin given by injection can take Penicillin G Potassium, which is not in short supply."

Answered by AI

Clinical Trials for Penicillin G Sodium

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17

All Sexes

Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4

Waitlist Available

Drug

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Have you considered Penicillin G Sodium clinical trials?

We made a collection of clinical trials featuring Penicillin G Sodium, we think they might fit your search criteria.

Image of Rady Childrens/UCSD in San Diego, United States.

Lung Ultrasound for Childhood Pneumonia

3 - 10

All Sexes

San Diego, CA

Pneumonia is a major cause of illness and death in children, with an annual incidence of about 3.3 per 1,000 in those under five years old, many requiring hospitalization. The diagnosis is challenging due to the absence of a universally accepted gold standard, leading to variability in emergency settings. Current guidelines recommend diagnosis based on history and physical examination, which do not reliably differentiate pneumonia from other respiratory infections or identify whether it is bacterial or viral in nature. This uncertainty can lead to the unnecessary use of antibiotics. Commonly used chest X-rays have limitations such as low sensitivity, moderate interobserver reliability, and the inability to distinguish bacterial from viral pneumonia. In contrast, lung ultrasound has shown high sensitivity and specificity for diagnosing pneumonia in children. However, lung ultrasound also cannot reliably distinguish between bacterial and viral causes and might lead to increased antibiotic prescriptions by detecting minor lung consolidations not seen on chest X-rays. Despite these issues, lung ultrasound is widely used in pediatric pulmonary assessment. The primary objective of the study is to determine if using lung ultrasound for diagnosing pneumonia in children can reduce antibiotic prescriptions compared to the standard care approach-which mainly relies on clinical diagnosis (often supplemented by chest X-ray and blood tests in selected cases). The secondary objective is to assess how frequently lung ultrasound impacts management decisions during a single clinical visit, beyond the information provided by history and physical examination. The third objective is to compare the diagnostic accuracy of lung ultrasound-supported diagnosis with existing diagnostic methods. The study hypothesizes that lung ultrasound results can act as a decision modifier, similar to other clinical tools and examination findings. However, a lack of consensus on specific lung ultrasound parameters and their clinical correlations contributes to variability in managing suspected pneumonia, potentially leading to antibiotic overuse. Eligible participants are children aged three to ten years who are in good general condition and clinically stable, presenting with signs and symptoms of lower respiratory tract infection indicative of pneumonia. Exclusion criteria include children outside the specified age range, those recently hospitalized, those who have undergone prior chest imaging, those already on antibiotic therapy, those with severe clinical instability, and those with underlying conditions predisposing them to severe or recurrent pneumonia. These criteria help ensure that the study population represents general pediatric community-acquired pneumonia cases, avoiding biases from high-risk patients. The ultimate goal of this study is to provide evidence on whether lung ultrasound can serve as a reliable tool to guide antibiotic prescriptions, thereby reducing unnecessary antibiotic use in the management of pediatric pneumonia.

Recruiting

Has No Placebo

Rady Childrens/UCSD (+3 Sites)

Niccolò Parri, MD